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In this study we report the development and optimization of two minigenome rescue systems for Nipah virus, a member of the Paramyxo-
viridae family. One is mediated by the T7 RNA polymerase supplied either by a constitutively expressing cell line or by transfection of expression
plasmids and is thus independent from infection with a helper virus. The other approach is based on RNA polymerase I-driven transcription, a
unique approach for paramyxovirus reverse genetics technology. Minigenome rescue was evaluated by reporter gene activities of (i) the two
different minigenome transcription systems, (ii) genomic versus antigenomic-oriented minigenomes, (iii) different ratios of the viral protein
expression plasmids, and (iv) time course experiments. The high efficiency and reliability of the established systems allowed for downscaling to
96-well plates. This served as a basis for the development of a high-throughput screening system for potential antivirals that target replication and
transcription of Nipah virus without the need of high bio-containment. Using this system we were able to identify two compounds that reduced
minigenome activity.
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Nipah virus (NiV), together with the closely related Hendra
virus (HeV), is a recently emerged deadly virus belonging to the
family Paramyxoviridae. Their genetic constitution, high
virulence, and wide host range set them apart from other
paramyxoviruses. NiV and HeV have been proposed to form a
new genus, Henipavirus, within the subfamily Paramyxoviri-
nae and are the only zoonotic paramyxoviruses with high
lethality (Chua et al., 2000a; Harcourt et al., 2000). NiV was
first identified in Malaysia in 1998/99 (Chua et al., 1999,
2000b; Goh et al., 2000) as the causative agent of an outbreak of⁎ Corresponding author. BioProtection Systems Corporation, 2901 South
Loop Drive, Suite 3360, Ames, IA 50010, USA. Fax: +1 515 296 3820.
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doi:10.1016/j.virol.2007.08.008respiratory illness in pigs and both encephalitis and massive
cerebral hemorrhages in humans (Parashar et al., 2000).
Subsequently in 2001–2005, NiV outbreaks occurred in
Australia, Malaysia, Singapore, India, and Bangladesh (Butler,
2004; Chadha et al., 2006; Eaton et al., 2006; Enserink, 2004;
Hsu et al., 2004; WHO, 2004). NiV infections can result in a 40
to 70% mortality rate, primarily from fatal encephalitis, and
there is increasing evidence of person-to-person transmissions
(Hsu et al., 2004; WHO, 2004). NiV is one of several newly
emerging and reemerging viruses, classified as a biosafety level
4 (BSL-4) pathogen and is designated a Category C Priority
Pathogen in the NIAID Biodefense Research Agenda. It has
been cited as a potential agent of bioterrorism due to its high
virulence, evidence of person-to-person transmission, and the
absence of vaccines or chemotherapeutics for this virus (Lam
and Chua, 2002). In addition to causing acute disease, 3 to 7%
34 A. Freiberg et al. / Virology 370 (2008) 33–44of infected patients exhibit a late onset or relapsed encephalitis
months to years after the initial infection (Tan et al., 2002),
thereby increasing the risk of community exposure.
As a member of the Paramyxoviridae family, NiV contains a
negative stranded, non-segmented RNA genome, with a gene
arrangement similar to that of other family members: 3′–
nucleocapsid protein (N)–phosphoprotein (P)/non-structural
proteins V, W and C–matrix protein (M)–fusionprotein (F)–
glycoprotein (G)–RNA-dependent RNA polymerase (L)–5′.
The genome length of 18,246 nucleotides (nt) is approximately
2700 nt longer than others in the family, only surpassed in
length by the recently discovered Beilong virus (Li et al., 2006).
Translation of its six transcription units results in the synthesis
of six major structural proteins and three non-structural proteins
V, W, and C from the P mRNA (Harcourt et al., 2000). Recently,
it has been shown that three of the viral structural proteins, N, P
and L, are necessary and sufficient for both transcription and
replication of an NiV minigenome (a reporter gene flanked by
the 5′ and 3′ non-coding regions of NiV) (Halpin et al., 2004).
Furthermore, this confirms that all cis-acting elements for
initiating transcription and replication reside within the terminal
genome sequences as shown for other Mononegavirales
including Ebola and Marburg virus (Groseth et al., 2005;
Mühlberger et al., 1998; Mühlberger et al., 1999), Respiratory
syncytial virus (Peeples and Collins, 2000), Sendai virus
(Calain and Roux, 1993), Borna disease virus (Rosario et al.,
2005; Schneider et al., 2003), and recently, NiV (Halpin et al.,
2004). Thus, the NiV minigenome rescue system provides a
powerful tool to study the processes of replication and
transcription and can eliminate biosafety concerns associated
with the use of infectious virus. The usefulness of similar
systems has been demonstrated for other BSL-4 pathogens such
as Zaire ebolavirus and Marburg virus (Mühlberger et al., 1998;
Mühlberger et al., 1999; Weik et al., 2005), Reston ebolavirus
(Boehmann et al., 2005; Groseth et al., 2005), Lassa fever virus
(Hass et al., 2004), Rift Valley fever virus (Gauliard et al., 2006;
Gerrard et al., 2007; Ikegami et al., 2005; Lopez et al., 1995;
Prehaud et al., 1997), Crimean Congo hemorrhagic fever virus
(Flick et al., 2003b), and Nipah virus (Halpin et al., 2004;
Yoneda et al., 2006). However, the majority of these systems
were dependent on the T7 RNA polymerase (T7) that had to be
supplied in trans. To avoid the necessity for an exogenous RNA
polymerase for minigenome expression, the endogenous RNA
polymerase I (Pol I) was used in this study to generate NiV
minigenomes. Initial concerns about the use of an enzyme
located in the nucleus to drive a reverse genetics system for
viruses exclusively replicating in the cytoplasm were not
justified. Export of Pol I transcripts from the nucleus to the
cytoplasm seems not to be a limiting factor for minigenome
rescue systems; we recently demonstrated this for several
members of the family Bunyaviridae (Flick et al., 2003a; Flick
et al., 2004; Flick et al., 2002; Flick et al., 2003b; Flick and
Pettersson, 2001; Gauliard et al., 2006) and for the Reston
ebolavirus (Groseth et al., 2005).
In summary, in this study we demonstrate for the first time
the successful use of an RNA Pol I-driven minigenome rescue
system, originally developed for influenza virus (Flick et al.,1996; Neumann et al., 1994; Zobel et al., 1993), for a
paramyxovirus. The concept of the present technology is
based on the transfection of cells with the NiV minigenome
system which results in the expression of CAT reporter gene
whose level of enzymatic activity directly reflects the extent of
viral replication. Such a helper virus-free system driven by an
endogenous enzyme has strong potential to be the basis for the
establishment of an efficient and reliable screening system for
potential antivirals and for the development of a reverse
genetics system for members of the Paramyxoviridae family.
Results
Establishment of a helper virus-free T7 RNA
polymerase-driven NiV minigenome rescue system
The previously published T7 RNA polymerase-driven
minigenome rescue system for NiV was dependent on infection
with the recombinant vaccinia virus MVA-T7 (Halpin et al.,
2004). To eliminate the additional step of MVA-T7 infection as
well as potential problems due to the introduced vaccinia virus
proteins, we established a helper virus-free T7 RNA polymer-
ase-based approach by using a cell line stably expressing the T7
polymerase (BHK-T7 724-5cl; provided by Ilya Frolov,
University of Texas Medical Branch, Galveston, TX) (Fig.
1A). Using this cell line and the previously described ratios for
the viral polymerase L, the nucleoprotein N, and the phospho-
protein P, we performed minigenome rescue in 24-well plates
resulting in reliable expression levels (Fig. 1B). To improve the
overall signal-to-noise ratio, cells were transfected with different
amounts of minigenome plasmids (0.05 to 0.4 μg) and cell
lysates were assayed for CAT activity 24 h post-transfection
(data not shown). An optimal signal-to-noise ratio was achieved
with 0.2 μg of pT7 NiV-CAT (−) (NiV minigenome in genomic
orientation) for a 24-well plate (Fig. 1B). In absence of the
expression plasmids L, N, and P, higher amounts of transfected
minigenome plasmids (i.e., N0.3 μg) showed strong background
of reporter gene expression levels indistinguishable from the
rescued specific signals. Omitting only one of the expression
plasmids (L or N or P) resulted also in high background signals
(data not shown). The background activity observed in the
presence of larger amounts of transfected minigenome plasmids
likely results from the recognition of cryptic promoter elements
within the reporter minigenome plasmid by the T7 polymerase
and/or cellular polymerases.
For even more flexibility and not to be restricted to one
specific cell line, a helper virus-free, completely plasmid-based
T7 NiV minigenome rescue technology was developed. To this
end, the T7 RNA polymerase was provided by co-transfection
of a plasmid-encoded T7 polymerase (Figs. 1A and C). Initially,
two different eukaryotic T7 polymerase expression systems
were used. One, pCAGGS/T7, is under the control of the
chicken β-actin promoter (kindly provided by Yoshihiro
Kawaoka, University of Wisconsin-Madison, USA) (Kobasa
et al., 1997; Niwa et al., 1991) and the other, pCMV-T7, is under
the control of the Cytomegalovirus (CMV) immediate early
promoter and enhancer element (kindly provided by Michèle
Fig. 1. Establishment of a helper virus-free T7 RNA polymerase- or Pol I-driven NiV minigenome rescue systems. (A) Schematic representation of different strategies
to deliver the T7 RNA polymerase for the T7 RNA polymerase-driven minigenome rescue system. (B) Helper virus-free T7 RNA polymerase-driven NiV minigenome
rescue. BHK-T7 cells in 24-well plates were transfected with 0.2 μg of minigenome and constant amounts of T7-driven support plasmids (NiV L, 0.2 μg; NiV N,
0.6 μg; NiV P, 0.4 μg). Lane 1 represents the negative control without co-transfected NiV L, N, and P. (C) Comparison of two different sources for T7 RNA polymerase
expression in a helper virus-free and completely plasmid-driven T7-based NiV minigenome rescue system. 293T/17 cells were co-transfected with pT7 NiV-CAT (−)
(0.2 μg) and all NiVexpression plasmids (NiV L, 0.2 μg; NiV N, 0.6 μg; NiV P, 0.2 μg) under T7-control along with 2 μg of pCAGGS/T7 (lanes 1 and 2) and pCMV-
T7 (lanes 3 and 4), respectively. Lanes 5 and 6 show transfection of the abovementioned NiV minigenome rescue system plasmids along with pCAGGS/T7 in HeLa
cells. In negative controls NiV L was omitted. (D) Comparison of T7- and Pol I-driven NiV minigenome rescue systems. 293T/17 cells were either transfected with
0.5 μg pPol I NiV-CAT (−) or 1.0 μg pT7 NiV-CAT (−) and co-transfected with support plasmids under either T7- or CMV-control (NiV L, 0.2 μg; NiV N, 0.6 μg; NiV
P, 0.2 μg). In all experiments 1 μg of pCAGGS/T7 was included as the source for the T7 RNA polymerase. In negative controls NiV L was omitted.
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kidney (293T/17) cells, stronger pT7 NiV-CAT (−) reporter
gene signals were observed with pCAGGS/T7 compared to the
pCMV-T7 expression plasmids (Fig. 1C, lane 2 versus 4). This
could be due to higher T7 expression levels in case of
pCAGGS/T7 resulting in better expression of NiV support
plasmids. In addition, this helper virus-free minigenome rescue
approach was also performed successfully with pCAGGS/T7 in
human epithelial HeLa cells (Fig. 1C, lane 6) demonstrating that
NiV minigenome rescue is possible without the use of MVA-T7
or the restricted use of T7 RNA polymerase stable expressing
cell lines and can be used in a variety of mammalian cell lines.
Based on the better signal intensity, we decided to use 293T/17
cells and the pCAGGS/T7 expression plasmid in all subsequent
experiments.
Establishment of an RNA polymerase I-driven minigenome
rescue system
Since a T7-driven minigenome system is still dependent on
the exogenous polymerase to generate the NiV minigenome
RNAs, we developed a system based on the cellular Pol I, a
unique approach within the field of paramyxoviruses. For this,
cDNAs of NiV minigenomes in genomic [vRNA, (−)] orantigenomic [cRNA, (+)] orientation that contained the CAT
reporter gene flanked by the human Pol I promoter and the
mouse Pol I terminator were designed. A Pol I-component-
containing plasmid (pLD9, unpublished data, L. Deflubé and R.
Flick) served as backbone to incorporate NiV minigenomes in
genomic and antigenomic orientation [pPol I NiV-CAT (−) and
pPol I NiV-CAT (+)] and was used in transfection experiments
to deliver functional NiV minigenomes. CMV-driven expres-
sion plasmids for NiV structural proteins were generated from
the previously described T7-dependent expression plasmids
(Halpin et al., 2004) by inserting the ORFs into the pcDNA 3.1
(Invitrogen) backbone.
One substantial advantage of the Pol I- versus the more
classical T7-driven system is the well defined transcription start
and termination sites. Pol I transcription results in RNAs
without any additional nucleotides on either end or other
modifications (e.g., poly A tail, cap structure) (Flick and
Hobom, 1999; Neumann et al., 1994; Zobel et al., 1993) and
therefore there is no need to add ribozyme sequences or use run-
off in vitro transcripts to generate (in subsequent, inefficient
steps) the functional minigenome. After transfection of the Pol
I-driven minigenome plasmids into eukaryotic cells (e.g., 293T/
17), the cellular Pol I generates minigenome transcripts with
authentic viral genome ends.
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In a first step, we tested our newly established Pol I-driven
NiV minigenome rescue system in 293T/17 cells for function-
ality. Transfection of all plasmids resulted in the expression of
CAT protein, as measured by its enzymatic activity (Fig. 1D,
lane 2). The reporter gene expression levels were strong and
showed no background signals (Fig. 1D, lane 1). After de-
monstrating the functionality of the Pol I-driven NiV mini-
genome rescue system, we directly compared the efficacies of
both minigenome rescue systems in the same cell line. For this,
293T/17 cells were transfected with NiV minigenome plasmids
[pT7 NiV-CAT (−) and pPol I NiV-CAT (−)] along with NiV L,
N, and P protein-expressing plasmids, either under T7- or CMV-
control, and pCAGGS/T7 (Fig. 1D). Negative controls, in
which no NiV polymerase support plasmid had been trans-
fected, are shown in the odd lanes. Taking into account that only
half the amount of pPol I NiV-CAT (−) was transfected
compared to pT7 NiV-CAT (−), the Pol I-driven minigenome
system showed a strong reporter gene signal and the level of
NiV minigenome expression is comparable with the T7-driven
minigenome system (Fig. 1D: lanes 2 versus 4). Overall, both
minigenome rescue systems exhibit comparable rescue effi-Fig. 2. Characterization of RNA polymerase I-driven NiV minigenome rescue syste
pPol I NiV-CAT minigenome plasmids [A: vRNA-oriented (genomic); B: cRNA-orie
N, 0.6 μg; NiV P, 0.2 μg), and pCAGGS/T7 (1 μg). In negative controls (odd lanes) N
minigenome rescue. 293T/17 cells were transfected with 1 μg pPol I NiV-CAT (+) mi
harvested at different time points post-transfection (10 to 86 h) and analyzed for repciencies and CAT activities in the same cell line. This result
indicates that the Pol I-driven minigenome system might be a
useful alternative to analyze transcription and replication
processes for paramyxoviruses and to serve as a control for
antiviral drug screening assays.
Analysis and characterization of Pol I-driven minigenome
replication
In the previously described experiments, minigenomes in
genomic (vRNA) orientationwere analyzed. In order to determine
if NiVminigenome replication in addition to transcription occurs,
minigenomes in cRNA orientation were used. The antigenomic
RNA transcripts need to first undergo a replication step
(cRNA→vRNA) in order to generate a functional template for
minigenome transcription (vRNA→mRNA). Hence, CAT
reporter gene expression in such experiments is dependent on
replication and transcription.
Relative minigenome expression levels of genomic [pPol I
NiV-CAT (−)] and antigenomic [pPol I NiV-CAT (+)] mini-
genomes in 293T/17 cells using various amounts of transfected
plasmid DNAs were determined (Fig. 2). For this, cells were
transfected in 24-well plates and harvested 48 h later for CATm. 293T/17 cells in 24-well plates were transfected with increasing amounts of
nted (antigenomic)], constant amounts of support plasmids (NiV L, 0.2 μg; NiV
iV L was omitted. (C) Time course experiment to determine most efficient NiV
nigenome plasmids and the NiV support plasmids as described above. Cells were
orter gene activity. In negative controls NiV L was omitted (odd lanes).
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genomic (Fig. 2A) and antigenomic (Fig. 2B) constructs. As
little as 0.05 μg of pPol I NiV-CAT (−) (Fig. 2A, lane 4) and
0.025 μg of pPol I NiV-CAT (+) (Fig. 2B, lane 2) were sufficient
to produce detectable levels of CAT activity. In the absence of
NiV support plasmids, only residual CAT background activity
was observed (Figs. 2A and B, odd lanes). The antigenomic
minigenome pPol I NiV-CAT (+) resulted in slightly stronger
reporter gene activities compared to the minigenome in genomic
orientation pPol I NiV-CAT (−), even at lower amounts of
transfected plasmid. We therefore decided to use this anti-
genomic-oriented minigenome in subsequent experiments.
We sought to further characterize the newly established Pol I-
driven NiV minigenome rescue system by performing time
course experiments to determine time points of maximum
reporter gene expression. To this end, 293T/17 cells were
transfected with optimal amounts of plasmids which resulted in
optimal signal-to-noise ratios (pPol I NiV-CAT (+): 1.0 μg, NiV
L: 0.2 μg, NiV N: 0.6 μg, NiV P: 0.2 μg) and harvested at
different time points between 10 h and 86 h post-transfection
(Fig. 2C). CAT activity was first detected at 24 h (Fig. 2C, lane
6) with a significant increase in signal between 27 and 40 h
post-transfection (Fig. 2C, lanes 8 and 10) and reached a plateau
after 52 h (Fig. 2C, lanes 14, 16, 18). We decided to harvest cells
in all subsequent experiments 48 h post-transfection. It is
noteworthy that, even after 86 h post-transfection, no back-
ground signal was observed when the expression plasmids for
L, N, and P were omitted (Fig. 2C, lane 17). Thus, the helper
virus-free Pol I-based system demonstrates a very good signal-
to-noise ratio.
Role of the support plasmid L:N:P ratios on minigenome
rescue efficiency
To further characterize the established Pol I-driven NiV
minigenome rescue system and to find conditions for the most
efficient rescue rates, we tested select ratios of the three viral
protein expression plasmids NiV L, N, and P in combination
with 1.0 μg of the antigenomic (cRNA-oriented) minigenome
pPol I NiV-CAT (+). Previously published amounts of L, N, and
P expression plasmids used with the T7-based approach of
0.2 μg, 0.6 μg, and 0.4 μg (molar ratio L:N:P of 0.3:1.7:1.0,
respectively) (Halpin et al., 2004) have been sub-optimal in our
hands (Fig. 3A, lanes 9, 22, 28, 46). To determine the plasmid
ratios for the most efficient minigenome rescue and to study the
requirement of trans-acting factors for optimal NiV minige-
nome transcription and replication, amounts of two support
plasmids were kept constant while the third was varied. In total,
we tested 40 combinations of expression plasmid ratios (Fig.
3A). Negative controls (omitting one of the support plasmids)
were always included in a group of six different conditions of all
NiV support plasmids (first lane in each experiment). Relative
CAT activities were evaluated using the TINA 2.09 program
(Raytest) (Fig. 3B). The molecular ratios of the transfected L:N:
P plasmids were calculated considering the sizes of 12,100 nt,
6,981 nt, and 7,514 nt of the L, N, and P expression plasmids,
respectively. We conclude that the Pol I-driven minigenomesystem is sensitive to minor changes in the ratios of the support
plasmids as even slight variations resulted in major changes in
CAT reporter expression levels. This suggests that NiV
minigenome transcription and replication are highly dependent
on optimal amounts and ratios of transfected NiV L, N, and P
expression plasmids. Interestingly, more than one ratio of the
three support plasmids that resulted in notably stronger
minigenome expression were identified. Subsequently, we
tested conditions resulting in peak levels from the titration
study in parallel for better comparison (Fig. 3C, lanes 2 to 14).
Additionally, these results were directly compared to the T7-
driven minigenome rescue system (Fig. 3C, lane 1). Higher
amounts of NiV P (0.2 versus 0.4 μg) seem to have an inhibiting
effect on minigenome expression (Fig. 3A, lanes 38 to 42 versus
44 to 48), while the amount of NiV N seems not to be critical in
the tested range (0.3 and 0.6 μg; e.g., Fig. 3A, lanes 14 to 18
versus 20 to 24). The same also applies to the amount of NiV L
as no difference in reporter gene activity is detectable within the
tested range (0.2 and 0.4 μg; Fig. 3A, lanes 26 to 30 versus 32 to
36). Overall, the transfection of more than 0.6 μg of NiV P or
less than 0.1 μg of NiV L and 0.2 μg NiV N did not result in any
detectable minigenome expression, suggesting that excess NiV
P interferes with efficient NiV minigenome transcription/
replication, whereas a minimal amount of NiV L and N is
required for minigenome expression.
Establishment of a high-throughput screening assay for
potential antiviral compounds
After development, characterization, and optimization of T7-
and Pol I-driven NiV minigenome rescue systems, we down-
scaled both for use in a screening assay for potential antiviral
compounds. Since classical thin layer chromatography-based
CAT assays are not suitable for high-throughput assays, a CAT
ELISA approach was used instead. For this, minigenome rescue
was characterized and optimized using 24-, 48-, and 96-well
plates to determine sensitivity and downscaling potential of the
established reporter systems. Transfecting minigenome-expres-
sing plasmids (0.1 μg of pPol I NiV-CAT (+) or pT7 NiV-CAT
(−)) and NiV L (0.1 μg), N (0.15 μg), and P (0.05 μg) protein-
expressing plasmids (either under T7- or CMV-control) along
with 0.25 μg pCAGGS/T7 in 293T/17 cells resulted in strong
and reproducible signals after an incubation time of 48 h. This
was confirmed by both enzymatic CAT reactions (data not
shown) and CAT ELISAs (Fig. 4A). These results suggest that
the NiV minigenome rescue systems have appropriate signal-to-
noise ratios as well as suitable sensitivity to be used in a 96-
well-based high-throughput screening assay for antiviral drugs.
Next, we validated the new system to prove our concept
of using the NiV minigenome rescue platform as a high-
throughput screen. Transfected 293T/17 cells in a 96-well
format were treated with potential antiviral compounds (at a
concentration of 20 μM) for 48 h and assayed for CAT activity.
The analyzed compounds are part of the 1990 compounds NCI
Diversity Set Library (kindly provided by M. Javad Aman,
USAMRIID, Fort Detrick, MD). We limited our initial
analysis to 80 samples to assess the suitability, efficacy, and
Fig. 3. Determination of trans-acting factors required for NiV minigenome transcription and replication. (A) 293T/17 cells were transfected with various amounts of
support plasmids expressing NiV L, N, and P, along with 1 μg of Pol I-driven cRNA-oriented NiV-CAT minigenome and 1 μg of pCAGGS/T7. For one NiV support
expression plasmid the amount of transfected DNAwas kept constant, while the amount for the other two was varied. Two different amounts of DNAwere chosen for
the expression plasmid that was kept constant. In the negative controls (always the first lane in a set of six different conditions) one of the expression plasmids (NiV L,
N, or P) was omitted. (B) Diagram of relative percentage of CAT activities measured in panel A. Relative CAT activities of each single condition were evaluated using
the TINA 2.09 program (Raytest). (C) Direct comparison of NiV minigenome expression levels using optimal ratios and amounts for NiV L, N, and P expression
plasmids. Lane 1 represents the completely T7-based and lanes 2 to 14 the Pol I-based NiV minigenome rescue system. The table above the CAT assays represents the
molar ratios between NiV L:N:P.
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4B, A1–H1 representing column number 1 of a 96-well plate)
and transfected cells (Fig. 4B, A12–H12 representing column
number 12 of a 96-well plate) were incubated with 1% DMSO,
the solvent for the compounds. Compounds showing inhibi-
tory effects resulting in a 50% decreased CAT activity (≤ODFig. 4. Establishment of high-throughput screening assays to identify antivirals
against NiV. (A) Minimization of NiV minigenome rescue systems. 293T/17
cells in 96-well plates were co-transfected with 0.5 μg pPol I NiV-CAT (+) or
pT7 NiV-CAT (−) minigenome plasmids, pCAGGS/T7 (0.25 μg), and NiV
expression plasmids under either T7- or CMV-control (NiV L, 0.1 μg; NiV N,
0.15 μg; NiV P, 0.05 μg). Reporter gene activity was measured using a CAT
ELISA Kit (Roche). Black bars indicate the pPol I NiV-CAT (+) and white bars
the pT7 NiV-CAT (−) minigenome. Negative controls omitting NiV L are
labeled as negative. Error bars for the positive controls were calculated out of 8
individual experiments. (B) Diagram of relative CAT activities of pPol I NiV-
CAT (+) minigenome plasmid after treatment with antiviral compounds (20 μM
final concentration). CAT activities were measured at 405 nm using the CAT
ELISA Kit (Roche). Columns of a 96-well plate are displayed beside each other
on the x-axis of the diagram. Negative (A1–H1, untransfected cells) and positive
(A12–H12, transfected cells) control reactions were performed by treating cells
with DMSO. The error bars were calculated out of 3 individual experiments. (C)
Diagram of relative CAT activities of pT7 NiV-CAT (−) minigenome plasmid
after treatment with potential antiviral compounds measured at 405 nm using the
CAT ELISA kit (Roche).1.0) were considered to exhibit anti-NiV activity. Two
compounds that decreased reporter gene activity could be
identified (Fig. 4B: wells A7 and F9). Cytotoxic effects of the
compounds inhibiting NiV minigenome expression were
excluded as shown by a viability test based on Trypan blue
staining (data not shown). Nevertheless, a lower level of
reporter gene expression could also be explained not only by
an NiV-specific mechanism but also by the possibility that
potential antiviral compounds alter the translation of the
reporter gene or the co-transfected support proteins. Subse-
quent experiments using live virus under BSL-4 conditions
will determine the specificity of the identified potential
antiviral compounds.
To confirm our initial hits and to exclude false positive hits
that simply interfere with the Pol I-based reverse genetics
technology, the candidate compounds A7 and F9 were
subsequently tested with our helper virus-free T7-driven NiV
minigenome rescue platform (Fig. 4C). Interestingly, compound
F9 showed a slightly stronger influence decrease of the CAT
activity with the T7-driven minigenome system. As a positive
control we used compounds A2 and D3, which had shown no
effect in the Pol I-driven minigenome screen. Both the T7
polymerase as well as the Pol I-driven minigenome screening
platform yielded similar results, therefore confirming the
interfering activity of Nipah viral transcription and replication
of some of the tested compounds.
In summary, the results presented in this study demonstrate
the suitability, efficacy, and practicability of the two plasmid-
based NiV minigenome rescue systems in a 96-well plate
format. This format can be used as high-throughput screening
platforms for antiviral compound libraries to identify molecules
that interfere with Nipah viral transcription and replication
processes.
Discussion
Previously reported minigenome rescue systems for mem-
bers of the family Paramyxoviridae have been based exclu-
sively on a bacteriophage T7 polymerase-driven reverse
genetics technology which requires the introduction of the
40 A. Freiberg et al. / Virology 370 (2008) 33–44exogenous T7 polymerase (Conzelmann and Schnell, 1994;
Grosfeld et al., 1995; Kato et al., 1996; Radecke et al., 1995;
Stillman et al., 1995). While this can be achieved in several
ways, including recombinant vaccinia virus infection and
transient expression from plasmid DNA (Fuerst et al., 1986;
Neumann et al., 2002a,b; Theriault et al., 2004), this step has the
potential to limit the system's efficiency due to technical
difficulties in achieving T7 expression in all cells. In contrast,
Pol I is a eukaryotic host cell polymerase which is localized in
the nucleoli, transcribing mainly rRNA genes (Sollner-Webb
and Tower, 1986). Using this enzyme to drive a reverse genetics
system provides a substantial advantage because it alleviates the
need to supply the polymerase in trans. The localization of Pol I
in the nucleus is one potential limitation of such a system,
especially for its application to viruses which replicate
exclusively in the cytoplasm. However, it was previously
employed successfully for the development of minigenomes for
several members of the Bunyaviridae (Flick et al., 2003a; Flick
et al., 2003b; Flick and Pettersson, 2001), Arenaviridae (Lee et
al., 2000), as well as for Filoviridae (Groseth et al., 2005) that
all replicate in the cytoplasm. Together with the data presented
herein, this indicates that Pol I-driven transcription is a broadly
applicable system for minigenome rescue, even for viruses not
replicating in the nucleus.
In the present study we described the establishment of an
RNA polymerase I-based minigenome rescue system for the
recently emerged Paramyxovirus NiVand the use of this system
as a high-throughput screening platform for potential antiviral
drugs interfering with viral transcription and replication
processes. To the best of our knowledge, this is the first report
demonstrating the successful use of a Pol I reverse genetics
technology for a member of the Paramyxoviridae and only the
second for a non-segmented negative-strand RNA virus after
Reston ebolavirus (Groseth et al., 2005). However, a recent
study demonstrated the successful rescue of Borna disease and
measles virus, both members of the Mononegavirales, by using
RNA polymerase I- and II-mediated expression of viral cRNA
(Martin et al., 2006).
Here we demonstrated transcription and replication of Pol I-
generated NiV minigenomes by the viral proteins L, N, and P
supplied by transfection of the corresponding expression
plasmids. Both genomic- and antigenomic-oriented minige-
nomes were rescued as demonstrated by strong CAT activity in
transfected cells (Figs. 2A and B). The antigenomic minigenome
produced comparable reporter gene activity to the minigenome
in genomic orientation (Fig. 2B). This is consistent with
observations with other Mononegavirales such as Sendai virus
(Calain and Roux, 1993) or Ebola and Marburg virus, where
minigenome rescue could be achieved using cRNA-oriented
minigenomes (Mühlberger et al., 1998; Mühlberger et al., 1999).
In fact, the first successful rescue of infectious rabies virus
entirely from cDNA was made possible only by the use of a
complete antigenome instead of genomic-oriented RNA
(Schnell et al., 1994). Since then, most full-length rescue
systems forMononegaviraleswere based on antigenomic cDNA
clones (Conzelmann, 2004; Enterlein et al., 2006; Kawaoka,
2004; Neumann et al., 2002b;Walpita and Flick, 2005). The heredescribed study also demonstrates that the antigenomic mini-
genomes produced virtually no background signal even at high
input levels (Fig. 2B) and long incubation times (Fig. 2C).
In order to evaluate the potential of the Pol I-driven
minigenome rescue system as an alternative to the more
common T7-driven platform, both systems were compared
directly. When equal amounts of both minigenome plasmids
(vRNA-oriented) were transfected along with the required
support plasmids, the Pol I-derived minigenomes produced
higher reporter gene expression levels compared to the T7-
driven construct (Fig. 2A, lane 6 and Fig. 1B, lane 2). In the
absence of protein expression plasmids, the level of CAT
expression from the minigenome plasmid alone was less with
the Pol I-driven system than that of the T7-driven minigenome,
demonstrating a better signal-to-noise ratio for the Pol I system.
Good signal-to-noise ratio is desirable for subsequent applica-
tions (e.g., determining time points for maximum reporter gene
activity or different ratios of viral protein support plasmids).
Based on these data, Pol I appears to be an attractive alternative
to T7 for the development of minigenome rescue systems.
Additionally, this technology eliminates the need for two
inefficient steps associated with a T7 system, namely the
introduction of an exogenous polymerase and ribozyme
cleavage to generate precise transcript ends.
Titration experiments with the support plasmids NiV L, N,
and P showed that replication and expression of the NiV
minigenome are affected most severely by increasing amounts
of NiV P (Fig. 3A, lanes 38 to 42 and 44 to 48). For other
members of the Mononegavirales, including Marburg virus
(Mühlberger et al., 1998), Sendai virus (Kato et al., 1996), and
Borna disease virus (Perez et al., 2003; Schneider et al., 2003), it
was shown that the ratio between P and N was critical for
reporter gene expression. In contrast, the amount of NiV N and
NiV L input DNA seems to be of less importance for mini-
genome rescue (Fig. 3A). Comparable results have been
obtained with Marburg virus (Mühlberger et al., 1998) and
Sendai virus (Kato et al., 1996).
In addition to the successful development of a Pol I-driven
system, we also established a helper virus-free, completely
plasmid-driven T7 RNA polymerase-based approach by using
(i) stable expressing BHK-T7 cells or (ii) transfected T7
expression plasmids.
As an application, we used both approaches to establish a
high efficient and reliable screening system for potential antiviral
compounds that interfere with the Nipah viral transcription and
replication processes. Due to the absence of vaccines or
chemotherapeutic agents for the treatment of NiV and HeV
infections, and the recently described potential for person-to-
person transmission during an NiVoutbreak in India/Bangladesh
(Chadha et al., 2006), it is of high priority to develop assays that
allow high-throughput screening for potential antivirals. With
the described NiV reverse genetics systems, we have established
tools which can be used for high-throughput screening of
libraries containing thousands of potential inhibitors. The
advantages of such a system are (i) lack of infectious material
thus no restriction to high containment laboratories, (ii) the
possibility of identifying antiviral compounds with a broad
41A. Freiberg et al. / Virology 370 (2008) 33–44spectrum of antiviral activity, (iii) viral and/or host cell pathways
necessary for viral replication can be targeted, and (iv)
compound-related toxicity is readily detectable.
The concept of the present technology is based on the
transfection of cells with the NiV minigenome system which
results in the expression of CAT reporter gene directly reflecting
the extent of viral replication. Monitoring the suppression of the
reporter gene activity would allow the identification of antiviral
compounds targeting replication and/or transcription of NiV.
One important advantage of using two minigenome rescue
systems (Pol I and T7) for screening large libraries is to reduce
false hits that are related to the respective expression strategy
and are not virus-specific. Additionally, the two alternative
minigenome systems are also valuable tools for basic research,
e.g., identifying cis-acting genomic elements, studying virus
encapsidation, transcription, replication, and genome packa-
ging, while eliminating biosafety constraints required for work
with infectious material. Although an infectious clone system
has been described for NiV recently (Yoneda et al., 2006) the
minigenome systems are invaluable tools to allow research in
BSL-2 laboratories.
Recently, two studies described the formation of NiV virus-
like particles (VLPs) when expressing NiV matrix, fusion, and
attachment proteins (Ciancanelli and Basler, 2006; Patch et al.,
2007). With the fully characterized minigenome rescue system
under Pol I and T7 control presented in this study, the next step
would be the establishment of a VLP system containing the
minigenome as a reporter to screen for antivirals that e.g.,
interfere with virus–receptor interactions.
In this study we only demonstrated the scalability of the
assay to high-throughput format as proof-of-concept. However,
development and validation of a functional and robust drug
screening assay will require further optimizations that are
beyond the scope of this study and will be pursued in the future.
Further investigations of the potential antiviral drugs found in
this study, including dose-dependent titrations and confirmative
live virus studies, will also be performed.
Materials and methods
Cell lines
293T/17 (a derivative of the human embryonic kidney cell
line 293T) and HeLa (human epithelial) cells (obtained from theTable 1
Oligonucleotides used for plasmid construction
Primer Sequence (5′→3′)
LD165 AATGAAGACGGTATTACCGAACAAGGGTA
LD166 AATGAAGACTTGGGGACCAAACAAGGGA
LD167 AATGAAGACTTGGGGACCGAACAAGGGT
LD168 AATGAAGACGGTATTACCAAACAAGGGA
LD179 AATCTCGAGCCATGGATAAATTGGAACTA
LD180 AATGGATCCTCAAATATTACCGTCAATGAT
LD181 AATGAAGACGGTCGACCATGAGTGATATC
LD182 AATGAAGACGGGATCTCACACATCAGCTC
Boldface: endonuclease restriction recognition sequences; underlining: NiV NCR seAmerican Type Cell Culture) were cultivated in Dulbecco's
Modified Eagle Medium (DMEM; Invitrogen), supplemented
with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA),
100 IU penicillin/ml, and 100 μg streptomycin/ml (Cellgro). T7
polymerase stably expressing baby hamster kidney cells (BHK-
T7 724-5cl) were kindly provided by I. V. Frolov (University of
Texas Medical Branch, Department of Microbiology and
Immunology, Galveston, TX). These cells were cultivated in
Alpha Modified Eagle Medium (α-MEM; Invitrogen), supple-
mented with 10% fetal bovine serum, 2 mM L-glutamine
(Invitrogen), 10 μg puromycin/ml (Sigma Aldrich), 100 IU
penicillin/ml, and 100 μg streptomycin/ml (Cellgro).
Plasmid construction
Nipah virus minigenome plasmids
Plasmids designed for transcription of NiV genomic [vRNA,
(−)] or antigenomic [cRNA, (+)] RNA by the cellular Pol I
contain the human Pol I promoter and the mouse Pol I
terminator (Flick et al., 2003b; Neumann et al., 1999; Zobel et
al., 1993). The NiV minigenome, a CAT reporter gene flanked
by the two non-coding regions (nucleotides 18,246–18,147 of
the 5′ trailer sequence and nucleotides 1–115 of the 3′ leader
sequence), was amplified by PCR using pNiV-CAT (Halpin et
al., 2004) as a template (kindly provided by P. Rota, Center for
Disease Control and Prevention). Oligonucleotides LD165/166
and LD167/168 were used for amplification of the minigenomes
in either genomic or antigenomic orientation, respectively
(Table 1). After cleavage with BbsI, the PCR fragments were
inserted between the Pol I promoter and terminator elements of
pLD 9, a vector similar to the previously published pRF42
(Flick and Pettersson, 2001) containing the human Pol I
promoter (unpublished data, L. Deflubé and R. Flick). The
resulting constructs were designated pPol I NiV-CAT (−) and
pPol I NiV-CAT (+).
Nipah virus protein expression plasmids under CMV-control
The NiV N and P ORFs were amplified by PCR from the
plasmids pNiV-N and pNiV-P (kindly provided by P. Rota,
Center of Disease Control and Prevention) (Halpin et al., 2004)
using primers LD181/182 and LD179/180, respectively.
Expression of the non-structural proteins C, V, and W from
the P gene was suppressed by silencing the C ORF through
mutation of the two consecutive start codons to ACG (Halpin etCloning product
AAGAAGAATCG pPol I NiV-CAT (−) [vRNA]
GAATATGGATACG
AAAGAAGAATCG pPol I NiV-CAT (+) [cRNA]
GAATATGGATACG
GTCAATG pCMV NiV-P
GTC
TTTGAAGAGGC pCMV NiV-N
TGACGAAATC
quences.
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vectors under the Cytomegalovirus (CMV) immediate early
promoter and enhancer element (pcDNA 3.1; Invitrogen) to
yield pCMV NiV-N and pCMV NiV-P, respectively. The
integrity of all constructs was verified by automated sequencing
over the full PCR amplification product and adjacent flanking
sequences (Macrogen Inc.).
Transfection
Sub-confluent cells (80 to 90%) seeded in tissue culture 24-
well plates were transfected with NiV minigenome plasmids
together with NiV L, N, and P expression plasmids. Transfec-
tion was carried out using Lipofectamine 2000 (Invitrogen
Carlsbad, CA) following the manufacturer's protocol. Briefly,
DNA was mixed with 20 μl Opti-MEM (Invitrogen, Carlsbad,
CA) and 2 μl of transfection reagent and incubated for 20 min at
room temperature. Subsequently, cells were incubated with the
DNA/Lipofectamine mixture and 100 μl of Opti-MEM for 3 h,
whereupon 1 ml of fresh medium with 2.8% FBS was added.
CATactivity was evaluated at 48 h post-transfection if not stated
otherwise. Negative controls omitting one of the expression
plasmids were compensated with pTM1. The plasmid pHL2823
(R. Flick and G. Hobom, unpublished data), which contains the
enhanced GFP ORF under control of a CMV promoter, was
transfected as a transfection efficiency control in all performed
experiments.
CAT assay
Cells from 24-well plates were harvested in 1 ml of PBS,
pelleted in a F45-24-11 rotor (5 min at 2800 rpm, Eppendorf),
resuspended in 55 μl of 250 mM Tris–hydrochloride (pH 7.4),
and lysed by three freeze–thaw cycles. Cell lysates were
incubated at 56 °C for 10 min. Subsequently, cells were spun for
10 min at 13,200 rpm. An enzymatic CAT reaction (FAST CAT
Kit; Invitrogen) was performed by mixing the lysate with 10 μl
of 9 mM Acetyl Coenzyme A (Sigma Aldrich), 10 μl
Component A (Fast CAT Kit; Invitrogen), and 0.25 M Tris–
hydrochloride (pH 7.4) to a final volume of 75 μl. After an
incubation time of 4 to 16 h at 37 °C samples were prepared for
thin-layer chromatography according to the FAST CAT Kit
protocol. The reaction products were visualized by UV-
illumination and documented by photography with a Gel Doc
2000 system (BioRad). Relative CAT activity was evaluated
using the TINA 2.09 program (Raytest).
Antiviral compounds and assay for specificity screening
The 80 tested antiviral compounds, kindly provided by M.
Javad Aman (United States Army Medical Research Institute
for Infectious Diseases), are part of the NCI Diversity set
library. This library represents a collection of 1990 compounds
accumulated out of 140,000 compounds available on plates.
These compounds were dissolved in DMSO and assayed for
their antiviral effect by using both the pT7 NiV-CAT (−) and
pPol I NiV-CAT (+) minigenome plasmids in 96-well plates.
Sub-confluent 293T/17 cells were transfected with the NiV
minigenome plasmid and the NiV L, N, and P expression
plasmids as described earlier. Three hours post-transfection theantiviral compounds were added in a 1:10 dilution (20 μM final
concentration) and incubated for 48 h. As control reactions,
untransfected (negative control) and transfected (positive
control) cells were treated only with the solvent DMSO (1%).
Minigenome expression levels were evaluated by using a CAT
enzyme-linked immunosorbent assay (ELISA) kit (Roche).
CAT ELISA
Quantification of CAT gene expression from 96-well plate
experiments was performed using a CAT ELISA kit (Roche)
following the manufacturer's protocol. Briefly, 2 days post-
transfection, cells were lysed in 100 μl of CAT lysis buffer for 1 h
at room temperature, and subsequently cell lysates were
transferred into individual wells of a 96-well plate coated with
an anti-CAT specific monoclonal antibody (Mab) and incubated
for 1 h at 37 °C. The wells were washed extensively with
washing buffer, and a second CAT-specific Mab labeled with
digoxigenin (DIG) was added to each well. After 1 h incubation
at 37 °C wells were washed again and incubated with a
peroxidase-coupled DIG-specific Fab fragment for 1 h at 37 °C.
In a last step, peroxidase substrate (without substrate enhancer)
was added, resulting in a peroxidase-mediated color reaction.
The colored product, which is directly correlated to the level of
CAT activity, was quantified spectrophotometrically at a
wavelength of 405 nm after an incubation time of around
20 min at room temperature using a SpectraMax M2 Microplate
Reader (Molecular Devices, Sunnyvale, CA). We defined
compounds as potential antiviral drugs (at the used test
concentration of 20 μM) as such whose effects resulted in a
50% decrease in reporter gene activity at 405 nm compared to
the average value of all tested compounds (corresponds to an OD
at 450 nm of 1.0 compared to the average value of 2.0±0.37).
Viability test
293T/17 cells were plated in a 96-well plate as described
above, and antiviral compounds are added in a final volume of
100 μl medium and harvested 48 h post-exposure. Trypan blue
staining was performed to distinguish between viable from non-
viable cells. For this, 25 μl of cells was diluted with 5 μl of the
dye and counted in a hemacytometer chamber. The percentage
of viable cells was calculated by using the following formula:
% Viability ¼ ð# viable cells counted=total # cells countedÞ
 100:
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